PDCD1 and non-small cell lung carcinoma: Owing to the success of antibodies targeting the PD-1/PD-L1 axis in the clinical trials against advanced melanoma, monoclonal PD-1 antibodies (Pembrolizumab and Nivolumb) were approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSLC), and other solid tumors (76–80).